<DOC>
	<DOC>NCT00944541</DOC>
	<brief_summary>This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV&lt; 50 cp/mL), controlled antiretroviral therapy (â‰¥ 6 months) and uncompleted immune restoration (CD4&lt;350 cells/mL and CD4 earning &lt;100 cells/mL during last 24 months). The study will include 60 patients whose follow up is carried out for 48 weeks. recruitment period will be maintained for 12 months.</brief_summary>
	<brief_title>Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV1 infection maravirocnaives patients CD4 less than 350 cells/mm3 viral load less than 50 cp/mL and CD4 earning less than 100 cells/mm3 during last 24 months HIV2 infection X4 tropism at inclusion pregnancy and breast feeding interferon, immunomodulatory drugs treatment or antiHIV vaccines and chemotherapy hypersensibility of peanut or soya</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>immune restoration</keyword>
	<keyword>treatment intensification</keyword>
</DOC>